Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MK 1084

Next Previous
Drug Profile

MK 1084

Alternative Names: MK-1084

Latest Information Update: 25 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme Corp.
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KRAS protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma; Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 16 Jul 2025 Phase-III clinical trials in Adenocarcinoma (Combination therapy, Inoperable/Unresectable, First-line therapy, Metastatic disease, Late-stage disease) in Israel (PO) (NCT06997497)
  • 16 Jul 2025 Phase-III clinical trials in Adenocarcinoma (Combination therapy, Inoperable/Unresectable, First-line therapy, Metastatic disease, Late-stage disease) in Taiwan (PO) (NCT06997497)
  • 08 Jun 2025 Phase I development is ongoing in Non-small cell lung cancer (Combination therapy, First-line therapy) in Israel, Panama, Poland, Switzerland and Taiwan (PO) (NCT05067283)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top